価格表
在庫・価格 : 2025年05月20日 09時31分 現在
商品名 | 商品コード | メーカー | 包装 | 価格 | 在庫 | リスト |
---|---|---|---|---|---|---|
FGF-19, Human, ELISA Kit(96well) <Fibroblast Growth Factor-19, ELISA Kit> データシート |
RD191107200R |
BLMバイオベンダー ラボラトリー BioVendor Laboratory Medicine, Inc. |
1 kit | ¥112,000 |
無 (未発注) |
追加 |
在庫・価格 : 2025年05月20日 09時31分 現在
使用文献
- No.: 1
-
文献情報:
Dost叩lov叩 I et al. Plasma concentrations of fibroblast growth factors 19 and 21 in patients with anorexia nervosa. J. Clin. Endocrinol. Metab. 2008 Sep;93(9):3627-32
Dost叩lov叩 I et al
2008/01/01
-
備考:
Species: Human, Applications: Serum,Plasma-EDTA,Plasma-Heparin,Plasma-Citrate -
参照:
- No.: 2
-
文献情報:
Bu転ga M et al. Effects of the intragastric balloon MedSil on weight loss, fat tissue, lipid metabolism, and hormones involved in energy balance. Obes Surg 2014 Jun;24(6):909-15
Bu転ga M et al
2014/01/01
-
備考:
-
参照:
- No.: 3
-
文献情報:
Eren F et al. Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease. Clin. Biochem. 2012 Jun;45(9):655-8
Eren F et al
2012/01/01
-
備考:
-
参照:
- No.: 4
-
文献情報:
Gallego-Escuredo JM et al. Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients. Int J Obes (Lond) 2015 Jan;39(1):121-9
Gallego-Escuredo JM et al
2015/01/01
-
備考:
-
参照:
- No.: 5
-
文献情報:
Gadaleta RM et al. Suppression of Hepatic Bile Acid Synthesis by a non-tumorigenic FGF19 analogue Protects Mice from Fibrosis and Hepatocarcinogenesis. Sci Rep 2018 Nov;8(1):17210
Gadaleta RM et al
2018/01/01
-
備考:
-
参照:
- No.: 6
-
文献情報:
Lee KJ et al. Expression of Fibroblast Growth Factor 21 and β-Klotho Regulates Hepatic Fibrosis through the Nuclear Factor-κB and c-Jun N-Terminal Kinase Pathways. Gut Liver 2018 07;12(4):449-456
Lee KJ et al
2018/01/01
-
備考:
-
参照:
- No.: 7
-
文献情報:
Li Z et al. Circulating FGF19 closely correlates with bile acid synthesis and cholestasis in patients with primary biliary cirrhosis. PLoS ONE 2017;12(6):e0178580
Li Z et al
2017/01/01
-
備考:
-
参照:
- No.: 8
-
文献情報:
Nielsen S et al. Chenodeoxycholic acid stimulates glucagon-like peptide-1 secretion in patients after Roux-en-Y gastric bypass. Physiol Rep 2017 Feb;5(3)
Nielsen S et al
2017/01/01
-
備考:
-
参照:
- No.: 9
-
文献情報:
van de Wiel SMW et al. Intestinal Farnesoid X Receptor Activation by Pharmacologic Inhibition of the Organic Solute Transporter α-β. Cell Mol Gastroenterol Hepatol 2018 Mar;5(3):223-237
van de Wiel SMW et al
2018/01/01
-
備考:
-
参照:
- No.: 10
-
文献情報:
Zhou M et al. Mouse species-specific control of hepatocarcinogenesis and metabolism by FGF19/FGF15. J. Hepatol. 2017 06;66(6):1182-1192
Zhou M et al
2017/01/01
-
備考:
-
参照:
- No.: 11
-
文献情報:
Z旦hrer E et al. Efficacy of docosahexaenoic acid-choline-vitamin E in paediatric NASH: a randomized controlled clinical trial. Appl Physiol Nutr Metab 2017 Sep;42(9):948-954
Z旦hrer E et al
2017/01/01
-
備考:
-
参照:
- No.: 12
-
文献情報:
Zhou M et al. Therapeutic FGF19 promotes HDL biogenesis and transhepatic cholesterol efflux to prevent atherosclerosis. J. Lipid Res. 2019 Mar;60(3):550-565
Zhou M et al
2019/01/01
-
備考:
-
参照:
- No.: 13
-
文献情報:
Zhou M et al. Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis. Nat Commun 2017 05;8:15433
Zhou M et al
2017/01/01
-
備考:
-
参照: